Matrix metalloproteinase-sensitive size-shrinkable liposomes targeting activated macrophages for the treatment of rheumatoid arthritis
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Protease and Inhibitor Mechanisms · Signaling Pathways in Disease
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (64)
Show source-provided references
1. Porous silicon-based nanomedicine for simultaneous management of joint inflammation and bone erosion in rheumatoid arthritis10.1021/acsnano.2c04491 ↗
2. H(2)O(2)/NIR-sensitive "two-step" nano theranostic system based hollow mesoporous copper sulfide/hyaluronic acid/JWH133 as an optimally designed delivery system for multidimensional treatment of RA
3. Engineered platelet microparticle-membrane camouflaged nanoparticles for targeting the Golgi apparatus of synovial fibroblasts to attenuate rheumatoid arthritis10.1021/acsnano.2c06584 ↗
4. Clematichinenoside AR inhibits the pathology of rheumatoid arthritis by blocking the circPTN/miR-145-5p/FZD4 signal axis
5. Multifunctional nanoparticles of sinomenine hydrochloride for treat-to-target therapy of rheumatoid arthritis via modulation of proinflammatory cytokines10.1016/j.jconrel.2022.05.016 ↗
6. Role of Nrf2 in rheumatoid arthritis10.1016/j.retram.2020.05.002 ↗
7. Ultrasound-augmented anti-inflammatory exosomes for targeted therapy in rheumatoid arthritis10.1039/D2TB01219G ↗
8. Macrophage-derived hybrid exosome-mimic nanovesicles loaded with black phosphorus for multimodal rheumatoid arthritis therapy10.1039/D2BM01274J ↗
9. Macrophages in inflammation, repair and regeneration10.1093/intimm/dxy054 ↗
10. alpha-Mangostin treats early-stage adjuvant-induced arthritis of rat by regulating the CAP-SIRT1 pathway in macrophages10.2147/DDDT.S348836 ↗
11. Withaferin-A, a steroidal lactone encapsulated mannose decorated liposomes ameliorates rheumatoid arthritis by intriguing the macrophage repolarization in adjuvant-induced arthritic rats10.1016/j.colsurfb.2017.04.046 ↗
12. Targeted delivery of p-coumaric acid encapsulated mannosylated liposomes to the synovial macrophages inhibits osteoclast formation and bone resorption in the rheumatoid arthritis animal model10.1016/j.ejpb.2018.10.010 ↗
13. Targeted delivery of morin, a dietary bioflavanol encapsulated mannosylated liposomes to the macrophages of adjuvant-induced arthritis rats inhibits inflammatory immune response and osteoclastogenesis10.1016/j.ejpb.2017.03.009 ↗
14. Hesperidin inhibits synovial cell inflammation and macrophage polarization through suppression of the PI3K/AKT pathway in complete Freund's adjuvant-induced arthritis in mice10.1016/j.cbi.2019.04.002 ↗
15. Polymer nanotherapeutics to correct autoimmunity10.1016/j.jconrel.2021.12.036 ↗
16. Monocytes in rheumatoid arthritis: circulating precursors of macrophages and osteoclasts and, their heterogeneity and plasticity role in RA pathogenesis10.1016/j.intimp.2018.10.016 ↗
17. Remodeling articular immune homeostasis with an efferocytosis-informed nanoimitator mitigates rheumatoid arthritis in mice10.1038/s41467-023-36468-2 ↗
18. Macrophage-targeted hydroxychloroquine nanotherapeutics for rheumatoid arthritis therapy10.1021/acsami.1c23429 ↗
19. Folate-modified triptolide liposomes target activated macrophages for safe rheumatoid arthritis therapy10.1039/D1BM01520F ↗
20. Palmitic acid-modified bovine serum albumin nanoparticles target scavenger receptor-A on activated macrophages to treat rheumatoid arthritis10.1016/j.biomaterials.2020.120296 ↗
21. Dextran sulfate-based MMP-2 enzyme-sensitive SR-A receptor targeting nanomicelles for the treatment of rheumatoid arthritis10.1080/10717544.2022.2032482 ↗
22. Dual-stimuli responsive polymeric micelles for the effective treatment of rheumatoid arthritis10.1021/acsami.1c04953 ↗
23. Matrix metalloproteinase-responsive PEGylated lipid nanoparticles for controlled drug delivery in the treatment of rheumatoid arthritis10.1021/acsabm.0c00242 ↗
24. Metalloproteinases in Rheumatoid arthritis: potential therapeutic targets to improve current therapies10.1016/bs.pmbts.2017.03.002 ↗
25. MMP-13 enzyme and pH responsive theranostic nanoplatform for osteoarthritis10.1186/s12951-020-00666-7 ↗
26. Cartilage-targeting and dual MMP-13/pH responsive theranostic nanoprobes for osteoarthritis imaging and precision therapy10.1016/j.biomaterials.2019.119520 ↗
27. Transdermal delivery of triptolide-phospholipid complex to treat rheumatoid arthritis10.1080/10717544.2021.1986603 ↗
28. The study of cellular mechanism of triptolide in the treatment of cancer, bone loss and cardiovascular disease and triptolide's toxicity10.2174/1574888X14666190301155810 ↗
29. Macrophage targeted triptolide micelles capable of cGAS-STING pathway inhibition for rheumatoid arthritis treatment10.1080/1061186X.2022.2070173 ↗
30. Targeted delivery of triptolide by dendritic cell-derived exosomes for colitis and rheumatoid arthritis therapy in murine models
31. Anti-angiogenic effect of triptolide in rheumatoid arthritis by targeting angiogenic cascade10.1371/journal.pone.0077513 ↗
32. Fabrication of a triptolide-loaded and poly-gamma-glutamic acid-based amphiphilic nanoparticle for the treatment of rheumatoid arthritis10.2147/IJN.S151233 ↗
33. Triptolide inhibits expression of inflammatory cytokines and proliferation of fibroblast-like synoviocytes induced by IL-6/sIL-6R-mediated JAK2/STAT3 signaling pathway10.1007/s11596-020-2302-1 ↗
34. Mechanochemical preparation of triptolide-loaded self-micelle solid dispersion with enhanced oral bioavailability and improved anti-tumor activity10.1080/10717544.2022.2069879 ↗
35. Triptolide-nanoliposome-APRPG, a novel sustained-release drug delivery system targeting vascular endothelial cells, enhances the inhibitory effects of triptolide on laser-induced choroidal neovascularization10.1016/j.biopha.2020.110737 ↗
36. Triptolide delivery: nanotechnology-based carrier systems to enhance efficacy and limit toxicity10.1016/j.phrs.2020.105377 ↗
37. Co-delivery of prednisolone and curcumin in human serum albumin nanoparticles for effective treatment of rheumatoid arthritis10.2147/IJN.S219413 ↗
38. An effective and safe treatment strategy for rheumatoid arthritis based on human serum albumin and Kolliphor((R)) HS 1510.2217/nnm-2019-0110 ↗
39. Advanced nanotheranostics of CRISPR/Cas for viral hepatitis and hepatocellular carcinoma
40. Rational construction of polycystine-based nanoparticles for biomedical applications10.1039/D2TB00581F ↗
41. An MMP-2 responsive liposome integrating antifibrosis and chemotherapeutic drugs for enhanced drug perfusion and efficacy in pancreatic cancer10.1021/acsami.5b11619 ↗
42. Myricitrin inhibits fibroblast-like synoviocyte-mediated rheumatoid synovial inflammation and joint destruction by targeting AIM210.3389/fphar.2022.905376 ↗
43. The DNA repair nuclease MRE11A functions as a mitochondrial protector and prevents T Cell pyroptosis and tissue inflammation10.1016/j.cmet.2019.06.016 ↗
44. A pH-Driven indomethacin-loaded nanomedicine for effective rheumatoid arthritis therapy by combining with photothermal therapy10.1080/1061186X.2022.2053539 ↗
45. Glycyrrhizin suppresses RANKL-induced osteoclastogenesis and oxidative stress through inhibiting NF-kappaB and MAPK and activating AMPK/Nrf210.1007/s00223-018-0425-1 ↗
46. Oxidative stress in inflammatory cells of patient with rheumatoid arthritis: clinical efficacy of dietary antioxidants10.1007/s10787-017-0397-1 ↗
47. Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis10.1038/s41584-018-0109-2 ↗
48. Cytokine networks in the pathogenesis of rheumatoid arthritis10.3390/ijms222010922 ↗
49. Colony stimulating factor-1 producing endothelial cells and mesenchymal stromal cells maintain monocytes within a perivascular bone marrow niche10.1016/j.immuni.2022.04.005 ↗
50. Osteoclast differentiation by RANKL and OPG signaling pathways10.1007/s00774-020-01162-6 ↗
51. Mechanisms of joint destruction in rheumatoid arthritis - immune cell-fibroblast-bone interactions10.1038/s41584-022-00793-5 ↗
52. Xiong Fu powder regulates the intestinal microenvironment to protect bones against destruction in collagen-induced arthritis rat models10.3389/fcimb.2022.854940 ↗
53. Exploring the effect of the Uyghur medicine Munziq Balgam on a collagen-induced arthritis rat model by UPLC-MS/MS-based metabolomics approach10.1016/j.jep.2023.116437 ↗
54. The immunomodulatory effects of Carapax Trionycis ultrafine powder on cyclophosphamide-induced immunosuppression in Balb/c mice10.1002/jsfa.10819 ↗
55. Anti-inflammatory effects of dietary polyphenols through inhibitory activity against metalloproteinases10.3390/molecules28145426 ↗
56. Protein arginine methyltransferase 1 upregulates matrix metalloproteinase-2/9 expression via Zeste Homolog 2 to promote human rheumatoid arthritis fibroblast-like synovial cell survival and metastasis10.1111/1756-185X.14454 ↗
57. Anti-proliferation and anti-inflammation effects of corilagin in rheumatoid arthritis by downregulating NF-kappaB and MAPK signaling pathways10.1016/j.jep.2021.114791 ↗
58. Influence of bone formation by composite scaffolds with different proportions of hydroxyapatite and collagen10.1016/j.dental.2020.12.006 ↗
59. Delayed inhibition of collagen deposition by targeting bone morphogenetic protein 1 promotes recovery after spinal cord injury10.1016/j.matbio.2023.03.006 ↗
60. The RANKL-RANK axis: a bone to thymus round trip10.3389/fimmu.2019.00629 ↗
61. Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis10.1080/14712598.2017.1263614 ↗
62. Stattic inhibits RANKL-mediated osteoclastogenesis by suppressing activation of STAT3 and NF-kappaB pathways10.1016/j.intimp.2018.03.021 ↗
63. A patent review on cathepsin K inhibitors to treat osteoporosis (2011–2021)10.1080/13543776.2022.2040480 ↗
64. Targeted delivery of triptolide by dendritic cell-derived exosomes for colitis and rheumatoid arthritis therapy in murine models10.1111/bph.15958 ↗